Robert Dillman | Chief Medical Officer
AIVITA Biomedical, Inc.

Robert O. Dillman, M.D. is a Clinical Professor of Medicine at the University of California Irvine and since 2016 has been the Chief Medical Officer of AIVITA Biomedical Inc., Irvine, CA. For 25 years, he directed the Hoag Cancer Center in Newport Beach, CA, where he also served as scientific director of the cell biology laboratory, education director for the cancer program, and director of cancer research. He was a founding member, 2-time Board Member, and a past president of the Society for the Immunotherapy of Cancer. His research career has focused on biotherapy and immunotherapy of cancer, including pioneering research on monoclonal antibodies and patient-specific immunotherapies such as ABMT, LAK, TIL, and autologous tumor antigen-based vaccines, especially dendritic cell vaccines. He has over 325 medical and scientific publications. He received a B.A. from Stanford, got his MD and internal medicine residency training at Baylor College of Medicine in Houston, followed by hematology and oncology fellowship training at the University of California San Diego. He is board-certified in medical oncology, hematology, and internal medicine.